Standard

MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential. / Veryaskina, Yuliya A.; Titov, Sergei E.; Kovynev, Igor B. et al.

In: Cancers, Vol. 17, No. 8, 1300, 12.04.2025.

Research output: Contribution to journalArticlepeer-review

Harvard

Veryaskina, YA, Titov, SE, Kovynev, IB, Fyodorova, SS, Berezina, OV, Zhurakovskij, IP, Antonenko, OV, Demakov, SA, Demenkov, PS, Ruzankin, PS, Tarasenko, AS, Pospelova, TI & Zhimulev, IF 2025, 'MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential', Cancers, vol. 17, no. 8, 1300. https://doi.org/10.3390/cancers17081300

APA

Veryaskina, Y. A., Titov, S. E., Kovynev, I. B., Fyodorova, S. S., Berezina, O. V., Zhurakovskij, I. P., Antonenko, O. V., Demakov, S. A., Demenkov, P. S., Ruzankin, P. S., Tarasenko, A. S., Pospelova, T. I., & Zhimulev, I. F. (2025). MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential. Cancers, 17(8), [1300]. https://doi.org/10.3390/cancers17081300

Vancouver

Veryaskina YA, Titov SE, Kovynev IB, Fyodorova SS, Berezina OV, Zhurakovskij IP et al. MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential. Cancers. 2025 Apr 12;17(8):1300. doi: 10.3390/cancers17081300

Author

Veryaskina, Yuliya A. ; Titov, Sergei E. ; Kovynev, Igor B. et al. / MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential. In: Cancers. 2025 ; Vol. 17, No. 8.

BibTeX

@article{f406fd40feb74b72bdfc7cbfbcc952b0,
title = "MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential",
abstract = "Background/Objectives: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) based on differences in both genetic and epigenetic factors contributes to the dynamics of tumor growth and efficacy of cytoreductive therapy, as well as considerably affecting disease prognosis. This study aimed to detect microRNAs (miRNAs) capable of improving prognostic accuracy in DLBCL patients. Methods: We performed miRNA sequencing in bone marrow (BM) samples collected from DLBCL patients. Next, the expression levels of miRNAs in lymph node (LN) samples (n = 43) and BM samples (n = 70) were analyzed by real-time RT-PCR in the group of DLBCL patients. Results: It was found that the expression levels of miRNA-10b, -100, -125a, -125b, -126, -143, -23a and let-7a were statistically significantly reduced in the group of DLBCL patients who had a poor prognosis compared to DLBCL patients with a favorable prognosis (p < 0.05). Kaplan–Meier survival analysis demonstrated that the upregulated expression of miRNA-23a, miRNA-125a, and miRNA-100 was associated with better overall survival in DLBCL patients. A statistically significant elevation in the expression levels of miRNA-151a, miRNA-148b and miRNA-192 in the BM samples was observed for DLBCL patients both with and without BM involvement compared to BM samples from non-cancerous blood disease (NCBD) patients (p < 0.05). Statistically significant upregulation of PD-L1, TIMP1, TOP2A, and TP53 was observed in BM samples from DLBCL patients with and without BM involvement in comparison with BM samples from NCBD patients (p < 0.05). Conclusions: miRNA-23a, miRNA-125a, and miRNA-100 were shown to be potential prognostically significant biomarkers in DLBCL patients. Changes in expression levels of miRNA-151a, miRNA-148b, miRNA-192, PD-L1, TIMP1, TOP2A, and TP53 reflect alterations in the BM without morphological or immunophenotypic signs of a DLBCL-related BM pathology.",
keywords = "biomarkers, diffuse large B-cell lymphoma, microRNA",
author = "Veryaskina, {Yuliya A.} and Titov, {Sergei E.} and Kovynev, {Igor B.} and Fyodorova, {Sofya S.} and Berezina, {Olga V.} and Zhurakovskij, {Igor P.} and Antonenko, {Oksana V.} and Demakov, {Sergei A.} and Demenkov, {Pavel S.} and Ruzankin, {Pavel S.} and Tarasenko, {Anton S.} and Pospelova, {Tatiana I.} and Zhimulev, {Igor F.}",
note = "This work has been supported by grants from the Russian Science Foundation (project no. № 20-14-00074-P). ",
year = "2025",
month = apr,
day = "12",
doi = "10.3390/cancers17081300",
language = "English",
volume = "17",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

RIS

TY - JOUR

T1 - MicroRNAs in Diffuse Large B-Cell Lymphoma (DLBCL): Biomarkers with Prognostic Potential

AU - Veryaskina, Yuliya A.

AU - Titov, Sergei E.

AU - Kovynev, Igor B.

AU - Fyodorova, Sofya S.

AU - Berezina, Olga V.

AU - Zhurakovskij, Igor P.

AU - Antonenko, Oksana V.

AU - Demakov, Sergei A.

AU - Demenkov, Pavel S.

AU - Ruzankin, Pavel S.

AU - Tarasenko, Anton S.

AU - Pospelova, Tatiana I.

AU - Zhimulev, Igor F.

N1 - This work has been supported by grants from the Russian Science Foundation (project no. № 20-14-00074-P).

PY - 2025/4/12

Y1 - 2025/4/12

N2 - Background/Objectives: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) based on differences in both genetic and epigenetic factors contributes to the dynamics of tumor growth and efficacy of cytoreductive therapy, as well as considerably affecting disease prognosis. This study aimed to detect microRNAs (miRNAs) capable of improving prognostic accuracy in DLBCL patients. Methods: We performed miRNA sequencing in bone marrow (BM) samples collected from DLBCL patients. Next, the expression levels of miRNAs in lymph node (LN) samples (n = 43) and BM samples (n = 70) were analyzed by real-time RT-PCR in the group of DLBCL patients. Results: It was found that the expression levels of miRNA-10b, -100, -125a, -125b, -126, -143, -23a and let-7a were statistically significantly reduced in the group of DLBCL patients who had a poor prognosis compared to DLBCL patients with a favorable prognosis (p < 0.05). Kaplan–Meier survival analysis demonstrated that the upregulated expression of miRNA-23a, miRNA-125a, and miRNA-100 was associated with better overall survival in DLBCL patients. A statistically significant elevation in the expression levels of miRNA-151a, miRNA-148b and miRNA-192 in the BM samples was observed for DLBCL patients both with and without BM involvement compared to BM samples from non-cancerous blood disease (NCBD) patients (p < 0.05). Statistically significant upregulation of PD-L1, TIMP1, TOP2A, and TP53 was observed in BM samples from DLBCL patients with and without BM involvement in comparison with BM samples from NCBD patients (p < 0.05). Conclusions: miRNA-23a, miRNA-125a, and miRNA-100 were shown to be potential prognostically significant biomarkers in DLBCL patients. Changes in expression levels of miRNA-151a, miRNA-148b, miRNA-192, PD-L1, TIMP1, TOP2A, and TP53 reflect alterations in the BM without morphological or immunophenotypic signs of a DLBCL-related BM pathology.

AB - Background/Objectives: The heterogeneity of diffuse large B-cell lymphoma (DLBCL) based on differences in both genetic and epigenetic factors contributes to the dynamics of tumor growth and efficacy of cytoreductive therapy, as well as considerably affecting disease prognosis. This study aimed to detect microRNAs (miRNAs) capable of improving prognostic accuracy in DLBCL patients. Methods: We performed miRNA sequencing in bone marrow (BM) samples collected from DLBCL patients. Next, the expression levels of miRNAs in lymph node (LN) samples (n = 43) and BM samples (n = 70) were analyzed by real-time RT-PCR in the group of DLBCL patients. Results: It was found that the expression levels of miRNA-10b, -100, -125a, -125b, -126, -143, -23a and let-7a were statistically significantly reduced in the group of DLBCL patients who had a poor prognosis compared to DLBCL patients with a favorable prognosis (p < 0.05). Kaplan–Meier survival analysis demonstrated that the upregulated expression of miRNA-23a, miRNA-125a, and miRNA-100 was associated with better overall survival in DLBCL patients. A statistically significant elevation in the expression levels of miRNA-151a, miRNA-148b and miRNA-192 in the BM samples was observed for DLBCL patients both with and without BM involvement compared to BM samples from non-cancerous blood disease (NCBD) patients (p < 0.05). Statistically significant upregulation of PD-L1, TIMP1, TOP2A, and TP53 was observed in BM samples from DLBCL patients with and without BM involvement in comparison with BM samples from NCBD patients (p < 0.05). Conclusions: miRNA-23a, miRNA-125a, and miRNA-100 were shown to be potential prognostically significant biomarkers in DLBCL patients. Changes in expression levels of miRNA-151a, miRNA-148b, miRNA-192, PD-L1, TIMP1, TOP2A, and TP53 reflect alterations in the BM without morphological or immunophenotypic signs of a DLBCL-related BM pathology.

KW - biomarkers

KW - diffuse large B-cell lymphoma

KW - microRNA

UR - https://www.mendeley.com/catalogue/f5958f56-aa4d-3343-8681-25e668408b4c/

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-105003407610&origin=inward&txGid=ba1d64fc7dafbd5dce72e44d0dae87e7

U2 - 10.3390/cancers17081300

DO - 10.3390/cancers17081300

M3 - Article

C2 - 40282476

VL - 17

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 8

M1 - 1300

ER -

ID: 65642412